Last reviewed · How we verify
PASIREOTIDE PAMOATE
PASIREOTIDE PAMOATE is a drug. It is currently FDA-approved (first approved 2014).
At a glance
| Generic name | PASIREOTIDE PAMOATE |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2014 |
Approved indications
Common side effects
Key clinical trials
- Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PASIREOTIDE PAMOATE CI brief — competitive landscape report
- PASIREOTIDE PAMOATE updates RSS · CI watch RSS
Frequently asked questions about PASIREOTIDE PAMOATE
What is PASIREOTIDE PAMOATE?
PASIREOTIDE PAMOATE is a Recombinant protein drug.
When was PASIREOTIDE PAMOATE approved?
PASIREOTIDE PAMOATE was first approved on 2014.
What development phase is PASIREOTIDE PAMOATE in?
PASIREOTIDE PAMOATE is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing